Category Archives: Drive

In its new therapy area insight series – Diabetes, IMARC Group, one of the world’s leading research and advisory firms, finds that Novel classes such as DPP-IV Inhibitors, GLP-Agonists and SGLT inhibitors will play a major role in driving the growth of major European Oral Antidiabetic markets. Findings from the reports suggest that in the next few years these classes will show a strong uptake both as a monotherapy and also as a combination with traditional Oral Antidiabetic cl......